Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings

被引:103
作者
Bertinchant, JP
Polge, A
Juan, JM
Oliva-Lauraire, MC
Giuliani, I
Marty-Double, C
Burdy, JY
Fabbro-Peray, P
Laprade, M
Bali, JP
Granier, C
de la Coussaye, JE
Dauzat, M
机构
[1] Univ Montpellier, Lab Cardiovasc Physiol, F-30900 Nimes 9, France
[2] Univ Nimes Hosp, Dept Biochem, F-30029 Nimes 9, France
[3] Univ Nimes Hosp, Dept Pathol, F-30029 Nimes 9, France
[4] Univ Nimes Hosp, Dept Epidemiol & Biostat, F-30029 Nimes 9, France
[5] CNRS, UMR 5094, Inst Biotechnol & Pharmacol, F-34060 Montpellier, France
[6] Sanofi Synthelabo Rech, F-34084 Montpellier, France
关键词
cardiac troponin I; cardiac troponin T; doxorubicin cardiomyopathy; echocardiography; histological study; rat;
D O I
10.1016/S0009-8981(03)00013-5
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Cardiac troponins I (cTnI) and T (cTnT) have been shown to be highly sensitive and specific markers of myocardial cell injury. We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model. Methods: Thirty-five Wistar rats were given 1.5 mg/kg DOX, i.v., weekly for up to 8 weeks for a total cumulative dose of 12 mg/kg BW. Ten rats received saline as a control group. cTnI was measured with Access((R)) (ng/ml) and a research immumoassay (pg/ml), and compared with cTnT, CK-MB mass and CK. By using transthoracic echocardiography, anterior and posterior wall thickness, LV diameters and LV fractional shortening (FS) were measured in all rats before DOX or saline, and at weeks 6 and 9 after treatment in all surviving rats. Histology was performed in DOX-rats at 6 and 9 weeks after the last DOX dose and in all controls. Results: Eighteen of the DOX rats died prematurely of general toxicity during the 9-week period. End-diastolic (ED) and end-systolic (ES) LV diameters/BW significantly increased, whereas LV FS was decreased after 9 weeks in the DOX group (p < 0.001). These parameters remained unchanged in controls. Histological evaluation of hearts from all rats given DOX revealed significant slight degrees of perivascular and interstitial fibrosis. In 7 of the 18 rats, degeneration and myocyte vacuolisation were found. Only five of the controls exhibited evidence of very slight perivascular fibrosis. A significant rise in cTnT was found in DOX rats after cumulative doses of 7.5 and 12 mg/kg in comparison with baseline (p < 0.05). cTnT found in rats after 12 mg/kg were significantly greater than that found after 7.5 mg/kg DOX. Maximal cTnI (pg/ml) and cTnT levels were significantly increased in DOX rats compared with controls (p = 0.006, 0.007). cTnI (ng/ml), CK-MB mass and CK remained unchanged in DOX rats compared with controls. All markers remained stable in controls. Analysis of data revealed a significant correlation between maximal cTnT and ED and ES LV diameters/BW (r=0.81 and 0.65; p < 0.0001). A significant relationship was observed between maximal cTnT and the extent of myocardial morphological changes, and between LV diameters/BW and histological findings. Conclusions: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes. Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments. (C) 2003 Elsevier Science B.V. All fights reserved.
引用
收藏
页码:39 / 51
页数:13
相关论文
共 45 条
  • [11] CAULFIELD JB, 1988, AM J PATHOL, V133, P298
  • [12] CARDIAC TROPONIN-T AND CREATINE-KINASE MB MASS CONCENTRATIONS IN CHILDREN RECEIVING ANTHRACYCLINE CHEMOTHERAPY
    FINK, FM
    GENSER, N
    FINK, C
    FALK, M
    MAIR, J
    MAURERDENGG, K
    HAMMERER, I
    PUSCHENDORF, B
    [J]. MEDICAL AND PEDIATRIC ONCOLOGY, 1995, 25 (03): : 185 - 189
  • [13] Ganz WI, 1996, ONCOLOGY, V53, P461
  • [14] The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: A meta-analysis
    Heidenreich, PA
    Alloggiamento, T
    Melsop, K
    McDonald, KM
    Go, AS
    Hlatky, MA
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (02) : 478 - 485
  • [15] Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin
    Herman, EH
    Zhang, J
    Lipshultz, SE
    Rifai, N
    Chadwick, D
    Takeda, K
    Yu, ZX
    Ferrans, VJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) : 2237 - 2243
  • [16] Herman EH, 1998, CANCER RES, V58, P195
  • [17] The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin and mitoxantrone-induced cardiotoxicity
    Herman, EH
    Zhang, J
    Rifai, N
    Lipshultz, SE
    Hasinoff, BB
    Chadwick, DP
    Knapton, A
    Chai, J
    Ferrans, VJ
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (04) : 297 - 304
  • [18] COMPARISON OF THE SEVERITY OF THE CHRONIC CARDIOTOXICITY PRODUCED BY DOXORUBICIN IN NORMOTENSIVE AND HYPERTENSIVE RATS
    HERMAN, EH
    ELHAGE, AN
    FERRANS, VJ
    ARDALAN, B
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 1985, 78 (02) : 202 - 214
  • [19] HERMAN EH, 1988, TOXICOL APPL PHARM, V92, P89
  • [20] JENSEN RA, 1984, J CARDIOVASC PHARM, V6, P186